300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Africa
Oceania
Oman
Poland
Puerto Rico
Sudan
Cameroon
Guernsey
Andorra
Colombia
China
Armenia
Kenya
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Botswana
Moldova
Seychelles
Paraguay
Japan
Ireland
Canada
United Kingdom
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Aier Eye Hospital Group, VC Fund

Aier Eye Hospital Group

VC Fund

Changsha, China

Aier Eye Hospital Group is a VC fund in Changsha focused on Medical Device and Medical. Aier Eye Hospital Group offers surgery for myopia; prevention and treatment for myopia; treatment for cataract, glaucoma, pediatric ophthalmology, fundus disease, lacrimal disease, and cornea and ocular surface; and eye shaping beauty services.

Total investments:
10
Last investment:
Lead investor:
30%

Last updated:

Industries Aier Eye Hospital Group invests in

Medical DeviceMedicalSoftwareHealth CareBiotechnology

Stages Aier Eye Hospital Group invests in

Series ASeries BPost-IPO EquitySeedSeries C

Countries Aier Eye Hospital Group invests in

ChinaHong Kong

Contacts

NameEmailPhoneSocials
Bang Chen
Li Li
Michael Lau

Sign up to unlock verified contacts

Unlock Contacts

2 more contacts available

Investment Focus

Industry

  • Medical Device 3 (30%)
  • Medical 2 (20%)
  • Software 2 (20%)
  • Health Care 2 (20%)
  • Biotechnology 2 (20%)
See all 18 industries →

Stage

  • Series A 2 (20%)
  • Series B 2 (20%)
  • Post-IPO Equity 2 (20%)
  • Seed 1 (10%)
  • Series C 1 (10%)
See all 7 stages →

Country

  • China 7 (70%)
  • Hong Kong 1 (10%)

Team

NameTitleInvestmentsLinksEmail
Bang Chen Founder
Founder Total investments: 0 Find email
Li Li Founder
Founder Total investments: 0 Find email
Michael Lau CEO
CEO Total investments: 0
Find email

Investments

CompanyDescriptionRoundLinks
Kangdesai Medical Technology Kangdesai Medical Technology
Kandesai is a personalized tumor immunotherapy developer, focusing on the development of immunotherapy platforms based on tumor neoantigens. It has independently developed 3 tumor drug pipelines based on neoantigens and innovative pipelines for liver cirrhosis with independent intellectual property rights. Help patients suppress tumor recurrenceand metastasis. Series A / Sep 22, 2025
Sieran Medical
Sieran Medical is a medical device company that provides precise and intelligent minimally invasive surgical treatment solutions for ophthalmology. $14.1M / Seed / Sep 05, 2024
Svision Svision
Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment. $43.1M / Series C / Mar 09, 2023
SIYO Bio-Tech SIYO Bio-Tech
SIYO Bio-Tech is a bioengineering company that focuses on research & innovation of microbial enzyme preparation technology. $31.7M / Series B / Feb 23, 2022
Svision Svision
Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment. Venture - Series Unknown / Dec 31, 2021
Zhaoke Ophthalmology Pharmaceutical Zhaoke Ophthalmology Pharmaceutical
Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform. $145M / Series B / Oct 12, 2020
The Kocla Smart Classes The Kocla Smart Classes
The Kocla Smart Classes provide centralized teaching and research services for education groups through the smart education platform, and enhance the interaction and communication between teachers, students, and parents through information technology. $5.1M / Post-IPO Equity / Mar 20, 2017
CloudClip CloudClip
CloudClip is a technology company that focuses on researching the myopia problem in young people and providing systematic solutions. They provide each user with customized eye-care training programs and help children develop a healthy eye-use habit. $1.4M / Series A / Dec 31, 2016
Qihoo 360 Technology Qihoo 360 Technology
Qihoo 360 Technology Co Ltd (Qihoo 360), formerly Qihoo Technology Company Limited, is engaged in the operations of Internet services and sales of third party anti-virus software in the People's Republic of China. It provides Internet and mobile security products in China. In January 2011, the Company had 328 million monthly active Internetsecurity product users, representing a user penetration rate of 83.9% in China. Its Internet and mobile security products include 360 Safe Guard and 360 Anti-virus, the Internet security products in China, with 301 million and 248 million monthly active users in January 2011, and 360 Mobile Safe, the mobile security product in China. The Company generates revenues primarily through offering the services, such as online advertising and Internet value-added services. Online advertising offers advertising services by providing marketing opportunities on its Websites and secure platform products to its advertising customers. $30M / Post-IPO Equity / Sep 28, 2016
The Kocla Smart Classes The Kocla Smart Classes
The Kocla Smart Classes provide centralized teaching and research services for education groups through the smart education platform, and enhance the interaction and communication between teachers, students, and parents through information technology. $7.1M / Series D / Jul 20, 2015

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Africa
Oceania
Oman
Poland
Puerto Rico
Sudan
Cameroon
Guernsey
Andorra
Colombia
China
Armenia
Kenya
Costa Rica
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Botswana
Moldova
Seychelles
Paraguay
Japan
Ireland
Canada
United Kingdom
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Aier Eye Hospital Group invest in?

Aier Eye Hospital Group invests primarily in Medical Device, Medical and Software startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Aier Eye Hospital Group?

Public channels for Aier Eye Hospital Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Aier Eye Hospital Group?

The team at Aier Eye Hospital Group includes Bang Chen (Founder), Li Li (Founder) and Michael Lau (CEO). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Aier Eye Hospital Group Aier Eye Hospital Group Find emails